Skip to main content
Top
Published in: Cardiology and Therapy 3/2022

Open Access 20-06-2022 | Anticoagulant | Original Research

Influence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy

Authors: Nakisa Khansari, Maryam Bagheri, Shahram Homayounfar, Jalal Poorolajal, Maryam Mehrpooya

Published in: Cardiology and Therapy | Issue 3/2022

Login to get access

Abstract

Introduction

Considering the anticoagulant actions of vitamin D, we hypothesize that vitamin D status might affect the required dose of warfarin for maintaining the therapeutic international normalized ratio (INR).

Methods

In a retrospective single-center cohort study, serum levels of 25-hydroxyvitamin D were assessed for 89 subjects receiving a stable dose of warfarin for 3 months or longer and had a stable INR between 2 and 3.5 for at least three consecutive visits. A warfarin sensitivity index (WSI), defined as the steady-state INR divided by the mean daily warfarin dose, was used for measuring the warfarin dose response. The relation between the serum level of 25-hydroxyvitamin D and WSI value and the difference in the mean WSI value between the subjects with different vitamin D status categories (sufficient, insufficient, and deficient) were assessed.

Results

Twenty-one subjects had vitamin D deficiency, 43 had vitamin D insufficiency, and only 25 had normal levels of 25-hydroxyvitamin D. Based on the multiple linear regression analysis, there was a significant but weakly positive correlation between WSI and 25-hydroxyvitamin D serum levels, as the value of WSI increases by almost 0.0027434 for every unit increase in 25-hydroxyvitamin D serum level (p value = 0.041). Using one-way ANOVA analysis, there was a trend in a significant difference between the groups with different vitamin D status categories regarding the mean WSI value (F = 2.95, p value = 0.057), as subjects with sufficient vitamin D state compared to those with vitamin D deficiency had a higher WSI value.

Conclusions

Although the study’s limitations limit our ability to draw definite conclusions, the present data suggest that in addition to other traditional factors, vitamin D status might also affect warfarin sensitivity and maintenance dose requirement. However, to more clearly explain this link, further studies with high involvement subjects are required.
Literature
1.
go back to reference Wadsworth D, Sullivan E, Jacky T, Sprague T, Feinman H, Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther. 2021;46(3):560–70.PubMedCrossRef Wadsworth D, Sullivan E, Jacky T, Sprague T, Feinman H, Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther. 2021;46(3):560–70.PubMedCrossRef
4.
go back to reference Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P, Milligan P, Grice G, Lenzini P, Rettie A. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326–31.PubMedCrossRef Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P, Milligan P, Grice G, Lenzini P, Rettie A. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326–31.PubMedCrossRef
5.
go back to reference Shi C, Yan W, Wang G, Wang F, Li Q, Lin N. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS ONE. 2015;10(12): e0144511.PubMedPubMedCentralCrossRef Shi C, Yan W, Wang G, Wang F, Li Q, Lin N. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS ONE. 2015;10(12): e0144511.PubMedPubMedCentralCrossRef
7.
go back to reference Nielsen PB, Lundbye-Christensen S, van der Male M, Larsen TB. Using a personalized decision support algorithm for dosing in warfarin treatment: a randomised controlled trial. Clin Trials Regul Sci Cardiol. 2017;25:1–6.CrossRef Nielsen PB, Lundbye-Christensen S, van der Male M, Larsen TB. Using a personalized decision support algorithm for dosing in warfarin treatment: a randomised controlled trial. Clin Trials Regul Sci Cardiol. 2017;25:1–6.CrossRef
8.
go back to reference Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K. Vitamin D: a review. Aust J General Pract. 2008;37(12):1002. Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K. Vitamin D: a review. Aust J General Pract. 2008;37(12):1002.
9.
go back to reference Issa L, Leong G, Eisman J. Molecular mechanism of vitamin D receptor action. Inflamm Res. 1998;47(12):451–75.PubMedCrossRef Issa L, Leong G, Eisman J. Molecular mechanism of vitamin D receptor action. Inflamm Res. 1998;47(12):451–75.PubMedCrossRef
10.
go back to reference Pike JW, Christakos S. Biology and mechanisms of action of the vitamin D hormone. Endocrinol Metab Clin. 2017;46(4):815–43.CrossRef Pike JW, Christakos S. Biology and mechanisms of action of the vitamin D hormone. Endocrinol Metab Clin. 2017;46(4):815–43.CrossRef
11.
go back to reference Thacher TD, Clarke BL. Vitamin D insufficiency. In: Mayo Clinic Proceedings: 2011: Elsevier; 2011, pp 50–60. Thacher TD, Clarke BL. Vitamin D insufficiency. In: Mayo Clinic Proceedings: 2011: Elsevier; 2011, pp 50–60.
14.
go back to reference Mohammad S, Mishra A, Ashraf MZ. Emerging role of vitamin D and its associated molecules in pathways related to pathogenesis of thrombosis. Biomolecules. 2019;9(11):649.PubMedCentralCrossRef Mohammad S, Mishra A, Ashraf MZ. Emerging role of vitamin D and its associated molecules in pathways related to pathogenesis of thrombosis. Biomolecules. 2019;9(11):649.PubMedCentralCrossRef
15.
go back to reference Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1α, 25-dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000;102(23):2867–72.PubMedCrossRef Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1α, 25-dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000;102(23):2867–72.PubMedCrossRef
16.
go back to reference Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1α, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood J Am Soc Hematol. 1998;92(1):160–7. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1α, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood J Am Soc Hematol. 1998;92(1):160–7.
17.
go back to reference Maillard C, Berruyer M, Serre CM, Amiral J, Dechavanne M, Delmas PD. Thrombomodulin is synthesized by osteoblasts, stimulated by 1, 25-(OH) 2D3 and activates protein C at their cell membrane. Endocrinology. 1993;133(2):668–74.PubMedCrossRef Maillard C, Berruyer M, Serre CM, Amiral J, Dechavanne M, Delmas PD. Thrombomodulin is synthesized by osteoblasts, stimulated by 1, 25-(OH) 2D3 and activates protein C at their cell membrane. Endocrinology. 1993;133(2):668–74.PubMedCrossRef
18.
go back to reference Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol. 2006;135(3):392–4.PubMedCrossRef Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol. 2006;135(3):392–4.PubMedCrossRef
19.
go back to reference Gholami K, Talasaz AH, Entezari-Maleki T, Salarifar M, Hadjibabaie M, Javadi MR, Dousti S, Hamishehkar H, Maleki S. The effect of high-dose vitamin D3 on soluble P-selectin and hs-CRP level in patients with venous thromboembolism: a randomized clinical trial. Clin Appl Thromb Hemost. 2016;22(5):483–9.PubMedCrossRef Gholami K, Talasaz AH, Entezari-Maleki T, Salarifar M, Hadjibabaie M, Javadi MR, Dousti S, Hamishehkar H, Maleki S. The effect of high-dose vitamin D3 on soluble P-selectin and hs-CRP level in patients with venous thromboembolism: a randomized clinical trial. Clin Appl Thromb Hemost. 2016;22(5):483–9.PubMedCrossRef
20.
go back to reference Blondon M, Biver E, Braillard O, Righini M, Fontana P, Casini A. Thrombin generation and fibrin clot structure after vitamin D supplementation. Endocr Connect. 2019;8(11):1447–54.PubMedPubMedCentralCrossRef Blondon M, Biver E, Braillard O, Righini M, Fontana P, Casini A. Thrombin generation and fibrin clot structure after vitamin D supplementation. Endocr Connect. 2019;8(11):1447–54.PubMedPubMedCentralCrossRef
21.
go back to reference Hejazi ME, Modarresi-Ghazani F, Hamishehkar H, Mesgari-Abbasi M, Dousti S, Entezari-Maleki T. The effect of treatment of vitamin D deficiency on the level of P-selectin and hs-CRP in patients with thromboembolism: a pilot randomized clinical trial. J Clin Pharmacol. 2017;57(1):40–7.PubMedCrossRef Hejazi ME, Modarresi-Ghazani F, Hamishehkar H, Mesgari-Abbasi M, Dousti S, Entezari-Maleki T. The effect of treatment of vitamin D deficiency on the level of P-selectin and hs-CRP in patients with thromboembolism: a pilot randomized clinical trial. J Clin Pharmacol. 2017;57(1):40–7.PubMedCrossRef
22.
go back to reference Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther. 2003;74(3):215–21.PubMedCrossRef Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther. 2003;74(3):215–21.PubMedCrossRef
23.
go back to reference Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost. 1999;81(03):396–9.PubMedCrossRef Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost. 1999;81(03):396–9.PubMedCrossRef
24.
go back to reference Rahman M, BinEsmael TM, Payne N, Butchart EG. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother. 2006;40(3):397–401.PubMedCrossRef Rahman M, BinEsmael TM, Payne N, Butchart EG. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother. 2006;40(3):397–401.PubMedCrossRef
25.
go back to reference Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.PubMedCrossRef Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.PubMedCrossRef
26.
go back to reference Mohd S, Sharma S, Mishra A, Ashraf MZ. Vitamin D and its relationship with the pathways related to thrombosis and various diseases. London: IntechOpen; 2021.CrossRef Mohd S, Sharma S, Mishra A, Ashraf MZ. Vitamin D and its relationship with the pathways related to thrombosis and various diseases. London: IntechOpen; 2021.CrossRef
27.
go back to reference Martinez-Moreno JM, Herencia C, Oca AM, Muñoz-Castañeda JR, Rodríguez-Ortiz ME, Díaz-Tocados JM, Peralbo-Santaella E, Camargo A, Canalejo A, Rodriguez M. Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. FASEB J. 2016;30(3):1367–76.PubMedCrossRef Martinez-Moreno JM, Herencia C, Oca AM, Muñoz-Castañeda JR, Rodríguez-Ortiz ME, Díaz-Tocados JM, Peralbo-Santaella E, Camargo A, Canalejo A, Rodriguez M. Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells. FASEB J. 2016;30(3):1367–76.PubMedCrossRef
28.
go back to reference Toderici M, de la Morena-Barrio ME, Padilla J, Minano A, Antón AI, Iniesta JA, Herranz MT, Fernández N, Vicente V, Corral J. Identification of regulatory mutations in SERPINC1 affecting vitamin D response elements associated with antithrombin deficiency. PLoS ONE. 2016;11(3): e0152159.PubMedPubMedCentralCrossRef Toderici M, de la Morena-Barrio ME, Padilla J, Minano A, Antón AI, Iniesta JA, Herranz MT, Fernández N, Vicente V, Corral J. Identification of regulatory mutations in SERPINC1 affecting vitamin D response elements associated with antithrombin deficiency. PLoS ONE. 2016;11(3): e0152159.PubMedPubMedCentralCrossRef
29.
go back to reference Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. In: Seminars in thrombosis and hemostasis: 1998: Copyright© 1998 by Thieme Medical Publishers, Inc.; 1998, pp 217–26. Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. In: Seminars in thrombosis and hemostasis: 1998: Copyright© 1998 by Thieme Medical Publishers, Inc.; 1998, pp 217–26.
30.
go back to reference Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25.PubMedCrossRef Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25.PubMedCrossRef
32.
go back to reference Equils O, Naiki Y, Shapiro A, Michelsen K, Lu D, Adams J, Jordan S. 1, 25-Dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol. 2006;143(1):58–64.PubMedPubMedCentralCrossRef Equils O, Naiki Y, Shapiro A, Michelsen K, Lu D, Adams J, Jordan S. 1, 25-Dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol. 2006;143(1):58–64.PubMedPubMedCentralCrossRef
33.
go back to reference Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–8.PubMedCrossRef Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–8.PubMedCrossRef
34.
go back to reference Timms P, Mannan N, Hitman G, Noonan K, Mills P, Syndercombe-Court D, Aganna E, Price C, Boucher B. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95(12):787–96.PubMedCrossRef Timms P, Mannan N, Hitman G, Noonan K, Mills P, Syndercombe-Court D, Aganna E, Price C, Boucher B. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95(12):787–96.PubMedCrossRef
35.
go back to reference Xu W, Hu X, Qi X, Zhu R, Li C, Zhu Y, Yin S, Cheng L, Zhu R. Vitamin D ameliorates angiotensin II-induced human endothelial progenitor cell injury via the PPAR-γ/HO-1 pathway. J Vasc Res. 2019;56(1):17–27.PubMedCrossRef Xu W, Hu X, Qi X, Zhu R, Li C, Zhu Y, Yin S, Cheng L, Zhu R. Vitamin D ameliorates angiotensin II-induced human endothelial progenitor cell injury via the PPAR-γ/HO-1 pathway. J Vasc Res. 2019;56(1):17–27.PubMedCrossRef
37.
go back to reference Brewer CL, Michos DE, Reis PJ. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets. 2011;12(1):54–60.PubMedCrossRef Brewer CL, Michos DE, Reis PJ. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets. 2011;12(1):54–60.PubMedCrossRef
38.
go back to reference Hammer Y, Soudry A, Levi A, Talmor-Barkan Y, Leshem-Lev D, Singer J, Kornowski R, Lev EI. Effect of vitamin D on endothelial progenitor cells function. PLoS ONE. 2017;12(5): e0178057.PubMedPubMedCentralCrossRef Hammer Y, Soudry A, Levi A, Talmor-Barkan Y, Leshem-Lev D, Singer J, Kornowski R, Lev EI. Effect of vitamin D on endothelial progenitor cells function. PLoS ONE. 2017;12(5): e0178057.PubMedPubMedCentralCrossRef
39.
go back to reference Wu W-X, He D-R. Low vitamin D levels are associated with the development of deep venous thromboembolic events in patients with ischemic stroke. Clin Appl Thrombosis Hemostasis. 2018;24(9_suppl):69S-75S.CrossRef Wu W-X, He D-R. Low vitamin D levels are associated with the development of deep venous thromboembolic events in patients with ischemic stroke. Clin Appl Thrombosis Hemostasis. 2018;24(9_suppl):69S-75S.CrossRef
40.
go back to reference Dehghani K, Nowrouzi A, Pourdavood AH, Rahmanian Z. Effect of Vitamin D deficiency in lower extremity and pulmonary venous thromboembolism. Biomed Res Therapy. 2019;6(4):3107–12.CrossRef Dehghani K, Nowrouzi A, Pourdavood AH, Rahmanian Z. Effect of Vitamin D deficiency in lower extremity and pulmonary venous thromboembolism. Biomed Res Therapy. 2019;6(4):3107–12.CrossRef
41.
go back to reference Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard B. 25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18 791 participants. J Thromb Haemost. 2013;11(3):423–31.PubMedCrossRef Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard B. 25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18 791 participants. J Thromb Haemost. 2013;11(3):423–31.PubMedCrossRef
42.
go back to reference Ehsanian R, Timmerman MA, Wright JM, McKenna S, Dirlikov B, Crew J. Venous thromboembolism is associated with lack of vitamin D supplementation in patients with spinal cord injury and low vitamin D levels. PM&R. 2019;11(2):125–34.CrossRef Ehsanian R, Timmerman MA, Wright JM, McKenna S, Dirlikov B, Crew J. Venous thromboembolism is associated with lack of vitamin D supplementation in patients with spinal cord injury and low vitamin D levels. PM&R. 2019;11(2):125–34.CrossRef
43.
go back to reference Gallerani M, Boari B, De Toma D, Salmi R, Manfredini R. Seasonal variation in the occurrence of deep vein thrombosis. Med Sci Monitor. 2004;10(5):CR191–6. Gallerani M, Boari B, De Toma D, Salmi R, Manfredini R. Seasonal variation in the occurrence of deep vein thrombosis. Med Sci Monitor. 2004;10(5):CR191–6.
44.
go back to reference Clauss R, Mayes J, Hilton P, Lawrenson R. The influence of weather and environment on pulmonary embolism: pollutants and fossil fuels. Med Hypotheses. 2005;64(6):1198–201.PubMedCrossRef Clauss R, Mayes J, Hilton P, Lawrenson R. The influence of weather and environment on pulmonary embolism: pollutants and fossil fuels. Med Hypotheses. 2005;64(6):1198–201.PubMedCrossRef
45.
go back to reference Ho J-D, Tsai C-Y, Liou S-W, Tsai RJ-F, Lin H-C. Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. Am J Ophthalmol. 2008;145(4):722-728.e723.PubMedCrossRef Ho J-D, Tsai C-Y, Liou S-W, Tsai RJ-F, Lin H-C. Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. Am J Ophthalmol. 2008;145(4):722-728.e723.PubMedCrossRef
46.
go back to reference Lindqvist P, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? AD-lightful hypothesis. J Thromb Haemost. 2009;7(4):605–10.PubMedCrossRef Lindqvist P, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? AD-lightful hypothesis. J Thromb Haemost. 2009;7(4):605–10.PubMedCrossRef
47.
go back to reference Banerjee A, Khemka VK. Augmentation of anticoagulant effect with vitamin D: possible therapeutic target for venous thromboembolism. Int J Hematol Blo Dis. 2017;2(1):1–5.CrossRef Banerjee A, Khemka VK. Augmentation of anticoagulant effect with vitamin D: possible therapeutic target for venous thromboembolism. Int J Hematol Blo Dis. 2017;2(1):1–5.CrossRef
48.
go back to reference Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, Farsetti S, Annunziata F, Paudice N, Salvadori M. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clin Nephrol. 2011;75(5):440–50.PubMedCrossRef Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, Farsetti S, Annunziata F, Paudice N, Salvadori M. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clin Nephrol. 2011;75(5):440–50.PubMedCrossRef
49.
go back to reference Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, Shikany JM, Raiesdana A, Heckbert SR, Manson JE, LaCroix AZ. The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. Thromb Haemost. 2015;113(05):999–1009.PubMedPubMedCentralCrossRef Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, Shikany JM, Raiesdana A, Heckbert SR, Manson JE, LaCroix AZ. The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. Thromb Haemost. 2015;113(05):999–1009.PubMedPubMedCentralCrossRef
50.
go back to reference Jorde R, Sneve M, Torjesen P, Figenschau Y, Hansen J-B. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res. 2010;125(5):e210–3.PubMedCrossRef Jorde R, Sneve M, Torjesen P, Figenschau Y, Hansen J-B. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res. 2010;125(5):e210–3.PubMedCrossRef
51.
go back to reference Elbers LP, Wijnberge M, Meijers JC, Poland DC, Brandjes DP, Fliers E, Gerdes VE. Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. Endocr Connect. 2018;7(2):325–33.PubMedPubMedCentralCrossRef Elbers LP, Wijnberge M, Meijers JC, Poland DC, Brandjes DP, Fliers E, Gerdes VE. Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. Endocr Connect. 2018;7(2):325–33.PubMedPubMedCentralCrossRef
52.
go back to reference Saliba W, Awad K, Ron G, Elias M. The effect of vitamin D supplementation on thrombin generation assessed by the calibrated automated thrombogram. Clin Appl Thromb Hemost. 2016;22(4):340–5.PubMedCrossRef Saliba W, Awad K, Ron G, Elias M. The effect of vitamin D supplementation on thrombin generation assessed by the calibrated automated thrombogram. Clin Appl Thromb Hemost. 2016;22(4):340–5.PubMedCrossRef
Metadata
Title
Influence of Vitamin D Status on the Maintenance Dose of Warfarin in Patients Receiving Chronic Warfarin Therapy
Authors
Nakisa Khansari
Maryam Bagheri
Shahram Homayounfar
Jalal Poorolajal
Maryam Mehrpooya
Publication date
20-06-2022
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 3/2022
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-022-00268-4

Other articles of this Issue 3/2022

Cardiology and Therapy 3/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.